Paradigm Diagnostics Announces the Addition of Industry Executive Mara Aspinall to the Board of Directors as Part of the Series B Extension Closing Totaling $15 Million

Paradigm Diagnostics, a leading precision medicine company focused on comprehensive cancer testing, announced the addition of Mara Aspinall, Managing Director of BlueStone Venture Partners to the Board of Directors as part of the closing of Paradigm’s $15 million Series B fundraising.Continue reading

New BIO Report: More Progress Needed in Innovation of Alzheimer’s Disease Therapeutics

WASHINGTON–(BUSINESS WIRE)–Today, the Biotechnology Innovation Organization (BIO) released a new report, The State of Innovation in Highly Prevalent Chronic Diseases Volume IV: Alzheimer’s Disease Therapeutics, the fourth in a series on the innovation landscape of highly prevalent, chronic diseases. This volume takes an in-depth look at the state of innovation for therapeutics in Alzheimer’s disease, which is expected to affect more than 13.8 million people in the United States by 2050 and cost well over $1 trillion annually.Continue reading